Pfizer is considering launching a nonprescription form of blockbuster cholesterol-lowering drug Lipitor after
a key patent expires in November, sources said. However, Pfizer is expected to have trouble doing so because of
the FDA's concern that patients will misuse statins without medical guidance. "We can confirm that we have strategic plans in place for Lipitor's loss of exclusivity and will comment no further at this time,"
said Pfizer spokesman Raymond Kerins.

Related Summaries